Media-News

Be the most trusted biotech company

2025-08-07

Henlius to Initiate a Phase 1 Multicenter Study in US of Its PD-L1 ADC HLX43 for the Treatment of Thymic Carcinoma
2025-08-06

Henlius Doses First Patient in Phase 2 Trial of HLX79 and HANLIKANG for Glomerulonephritis
2025-07-31

First India Shipment of Henlius' Serplulimab
2025-07-28

CHMP Recommends EU Approval of Henlius’ Denosumab Biosimilar HLX14
2025-07-25

Henlius to Present Latest Results on ADC and IO Therapies in Lung Cancer at 2025 WCLC
2025-07-25

From China’s First to Industry Benchmark | Five Years Since HANQUYOU's Global Approval, Benefiting over 260,000 Patients Worldwide
2025-07-14

Henlius’ HLX22 International Multicentre Phase 3 Head-to-Head Trial Administers First Dose to US Patient in HER2+ GC
2025-07-09

Henlius Receives Global Regulatory Approvals for Phase 2 MRCT of Its PD-L1 ADC HLX43 on NSCLC
2025-07-02

Henlius Receives New EMA GMP Certification, Accelerating European Market Entry of Two Biosimilar Candidates